Using pamiparib for treating resistant non-small cell lung cancer

Double Arm Single Center Clinical Trial of Pamiparib (BGB-290) for EGFR TKIs Resistant Non-small Cell Lung Cance

This study is testing if a new drug called pamiparib can help people with non-small cell lung cancer that has stopped responding to previous treatments.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Affiliated Hospital of Jiangnan University (Academic / other)
• Locations: 1 site (Wuxi, Jiangsu)
• Trial ID: NCT05573373 on ClinicalTrials.gov

What this trial studies

This study investigates the efficacy and safety of pamiparib in patients with non-small cell lung cancer (NSCLC) that has become resistant to EGFR-TKIs. It employs a single-center, dual-arm, open-label design to assess how well pamiparib works in this patient population. The trial focuses on patients who have experienced disease progression after treatment with first-generation and/or second-generation TKIs, as well as those who have progressed after third-generation EGFR-TKI treatment. The study aims to explore new treatment options for patients facing limited alternatives due to acquired resistance.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed non-small cell lung cancer that has progressed after EGFR-TKI treatment.

Not a fit: Patients with other concurrent cancers or those who have not experienced progression after EGFR-TKI treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with EGFR-TKI resistant NSCLC.

How similar studies have performed: While PARP inhibitors are a relatively new class of therapy, similar studies have shown promise in treating other cancers, indicating potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

1. Male or female patients: ≥18 years old
2. Histologically or cytologically confirmed non-small cell lung cancer, and the disease has progressed after first-generation and/or second-generation TKIs treatment with first-line therapy and no T790 mutation, or after third-generation EGFR-TKI treatment After the disease progresses, the guidelines do not recommend a standard protocol.
3. No other concurrent cancer.
4. At least one previously unirradiated lesion that can be accurately measured at baseline with longest diameter ≥ 10 mm (must have a short lymph node excluding axis ≥ 15 mm) according to RECIST criteria with computed tomography (CT), magnetic resonance imaging (MRI) or clinical examination for accurate repeated measures. Or an unevaluable lesion, including but not limited to pleural and ascites, bone metastasis, etc.
5. ECOG physical condition score: 0-3 points.
6. Expected survival period ≥ 3 months.
7. The function of major organs is good, that is, the relevant inspection indicators within 14 days before randomization meet the following requirements: a) Routine blood test:i. Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); ii. Neutrophil count \> 1.5×109/L; iii. Platelet count ≥ 90×109/L; b) Biochemical examination: i. Total bilirubin ≤ 1.5×ULN (upper limit of normal); ii. Blood alanine aminotransferase (ALT) or blood aspartate aminotransferase (AST) ≤ 2.5×ULN; if liver metastasis, ALT or AST ≤ 5×ULN; iii. Endogenous creatinine clearance ≥ 60 ml/min (Cockcroft-Gault formula); c) Cardiac Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ 50%.
8. Sign the informed consent.
9. The patient is willing and able to comply with the protocol during the study, including receiving treatment and scheduled visits and examinations, including follow-up.

Exclusion Criteria:

1. Participated in clinical trials of other drugs within four weeks.
2. Histologically or cytologically confirmed small cell, large cell neuroendocrine or carcinoid.
3. There are clinical symptoms or diseases of the heart that cannot be well controlled, such as: NYHA class 2 or higher heart failure, unstable angina pectoris, myocardial infarction within 1 year, clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention of patients.
4. For female subjects: should be surgically sterilized, postmenopausal patients, or agree to use a medically approved contraceptive during the study treatment period and within 6 months after the end of the study treatment period; Serum or urine pregnancy test must be negative within 7 days and must be non-nursing. Male subjects: Patients who should be surgically sterilized, or who agree to use a medically-approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period.
5. The patient has active pulmonary tuberculosis, bacterial or fungal infection (≥ grade 2 of NCI-CTC, 3rd edition); HIV infection, HBV infection, HCV infection.
6. Those who have a history of psychotropic substance abuse and cannot quit or have mental disorders.
7. The subject has any active autoimmune disease or has a history of autoimmune disease (such as the following, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism, thyroid Reduced function; subjects with vitiligo or complete remission of asthma in childhood without any intervention in adulthood can be included; subjects with asthma requiring bronchodilator medical intervention are not included).
8. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.

Where this trial is running

Wuxi, Jiangsu

• Affiliated Hospital of Jiangnan University — Wuxi, Jiangsu, China (Recruiting)

Study contacts

• Principal investigator: liu quan, doctor — Affiliated Hospital of Jiangnan University
• Study coordinator: liu quan, doctor

Conditions Carcinoma, Non-Small-Cell Lung; EGF-R Positive Non-Small Cell Lung Cancer